310 related articles for article (PubMed ID: 23578674)
21. Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging Abnormalities.
Sima DM; Phan TV; Van Eyndhoven S; Vercruyssen S; Magalhães R; Liseune A; Brys A; Frenyo P; Terzopoulos V; Maes C; Guo J; Hughes R; Gabr RE; Huijbers W; Saha-Chaudhuri P; Curiale GG; Becker A; Belachew S; Van Hecke W; Ribbens A; Smeets D
JAMA Netw Open; 2024 Feb; 7(2):e2355800. PubMed ID: 38345816
[TBL] [Abstract][Full Text] [Related]
22. Amyloid-Related Imaging Abnormalities in an Aged Squirrel Monkey with Cerebral Amyloid Angiopathy.
Heuer E; Jacobs J; Du R; Wang S; Keifer OP; Cintron AF; Dooyema J; Meng Y; Zhang X; Walker LC
J Alzheimers Dis; 2017; 57(2):519-530. PubMed ID: 28269776
[TBL] [Abstract][Full Text] [Related]
23. Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.
Söderberg L; Johannesson M; Gkanatsiou E; Nygren P; Fritz N; Zachrisson O; Rachalski A; Svensson AS; Button E; Dentoni G; Osswald G; Lannfelt L; Möller C
Sci Rep; 2024 May; 14(1):10868. PubMed ID: 38740836
[TBL] [Abstract][Full Text] [Related]
24. Imaging of Amyloid-Related Imaging Abnormalities (ARIA).
Urbach H; Linn J; Hattingen E; Fiebach J
Rofo; 2024 Apr; 196(4):363-369. PubMed ID: 37995736
[TBL] [Abstract][Full Text] [Related]
25. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
Brody M; Liu E; Di J; Lu M; Margolin RA; Werth JL; Booth K; Shadman A; Brashear HR; Novak G
J Alzheimers Dis; 2016 Oct; 54(4):1509-1519. PubMed ID: 27589523
[TBL] [Abstract][Full Text] [Related]
26. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
[TBL] [Abstract][Full Text] [Related]
27. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.
Zago W; Schroeter S; Guido T; Khan K; Seubert P; Yednock T; Schenk D; Gregg KM; Games D; Bard F; Kinney GG
Alzheimers Dement; 2013 Oct; 9(5 Suppl):S105-15. PubMed ID: 23583235
[TBL] [Abstract][Full Text] [Related]
28. Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-Aβ Autoantibodies.
Piazza F; Caminiti SP; Zedde M; Presotto L; DiFrancesco JC; Pascarella R; Giossi A; Sessa M; Poli L; Basso G; Perani D
Neurology; 2022 Sep; 99(12):e1265-e1277. PubMed ID: 35940900
[TBL] [Abstract][Full Text] [Related]
29. Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities.
Hardy J; Schott JM
Neurology; 2024 Feb; 102(3):e208096. PubMed ID: 38165303
[TBL] [Abstract][Full Text] [Related]
30. Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid.
Yaari R; Holdridge KC; Choi J; Donohue MC; Kantarci K; Jack CR; Zuk SM; Sims JR; Johnson KA; Aisen PS; Sperling RA
J Prev Alzheimers Dis; 2022; 9(4):617-624. PubMed ID: 36281665
[TBL] [Abstract][Full Text] [Related]
31. A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease.
Muralidharan KK; Karumanchi S; Kowalski KG; Burkett P; Chapel S; Rajagovindan R; Nestorov I
J Clin Pharmacol; 2022 Aug; 62(8):1030-1046. PubMed ID: 35285968
[TBL] [Abstract][Full Text] [Related]
32. Validation of 3- and 5-point severity scales to assess ARIA-E.
Bracoud L; Klein G; Lyons M; Scelsi MA; Wojtowicz J; Bullain S; Purcell D; Fiebach JB; Barakos J; Suhy J
Alzheimers Dement (Amst); 2023; 15(4):e12503. PubMed ID: 38026755
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.
Carlson C; Estergard W; Oh J; Suhy J; Jack CR; Siemers E; Barakos J
Alzheimers Dement; 2011 Jul; 7(4):396-401. PubMed ID: 21784350
[TBL] [Abstract][Full Text] [Related]
34. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease.
Carlson C; Siemers E; Hake A; Case M; Hayduk R; Suhy J; Oh J; Barakos J
Alzheimers Dement (Amst); 2016; 2():75-85. PubMed ID: 27239538
[TBL] [Abstract][Full Text] [Related]
35. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Chen T; O'Gorman J; Castrillo-Viguera C; Rajagovindan R; Curiale GG; Tian Y; Patel D; von Rosenstiel P; von Hehn C; Salloway S; Hock C; Nitsch RM; Haeberlein SB; Sandrock A; Singhal P
Alzheimers Dement; 2024 May; 20(5):3406-3415. PubMed ID: 38567735
[TBL] [Abstract][Full Text] [Related]
36. Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-β Therapy.
Agarwal A; Gupta V; Brahmbhatt P; Desai A; Vibhute P; Joseph-Mathurin N; Bathla G
Radiographics; 2023 Sep; 43(9):e230009. PubMed ID: 37651273
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study.
Salloway S; Marshall GA; Lu M; Brashear HR
Curr Alzheimer Res; 2018; 15(13):1231-1243. PubMed ID: 30129411
[TBL] [Abstract][Full Text] [Related]
38. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
[TBL] [Abstract][Full Text] [Related]
39. Monitoring Blood-Brain Barrier Integrity Following Amyloid-β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model.
Blockx I; Einstein S; Guns PJ; Van Audekerke J; Guglielmetti C; Zago W; Roose D; Verhoye M; Van der Linden A; Bard F
J Alzheimers Dis; 2016 Sep; 54(2):723-35. PubMed ID: 27567811
[TBL] [Abstract][Full Text] [Related]
40. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
Piazza F; Winblad B
J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
